Published in:
01-01-2022 | Anakinra | New Therapies for Cardiovascular Disease (AA Bavry and MR Massoomi, Section Editors)
Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis
Authors:
Tom Kai Ming Wang, Allan L. Klein
Published in:
Current Cardiology Reports
|
Issue 1/2022
Login to get access
Abstract
Purpose of Review
We reviewed the contemporary literature and clinical trials to discuss the applications of the interleukin-1 (IL-1) inhibitor rilonacept to treat pericarditis, with regards to pathophysiology, pharmacology, efficacy, and safety.
Recent Findings
Rilonacept is an emerging novel agent for treating recurrent pericarditis, with phase II and III clinical trials recently published. Rilonacept rapidly resolved pericarditis pain and inflammation, markedly reduced recurrent pericarditis episodes, and had few adverse events indicating a high safety profile.
Summary
Recurrent pericarditis is associated with significant morbidity and unmet need for novel therapies. Inflammasomes and the IL-1 pathways were found to be critical in its pathophysiology, leading to IL-1 inhibitors being developed. The high efficacy and safety of rilonacept for recurrent pericarditis means it could potentially be considered as a second-line therapy ahead of or as an alternative to corticosteroids, and highlight the great promise of targeted immunomodulatory therapy in this field.